Cytoreductive nephrectomy for metastatic renal cell carcinoma: A review of the historical literature and its role in the era of targeted molecular therapy - Abstract

Renal cell carcinoma presents with metastatic disease in approximately 30% cases.

While surgical intervention remains the standard of care for organ confined disease, its role is limited in the management of metastatic disease. Over the last decade, cytoreductive nephrectomy prior to immunotherapy has demonstrated significant improvement in overall survival for appropriately selected patients. This review summarizes the evidence for the role of cytoreductive nephrectomy in combination with immunotherapy and discusses its potential role in the current era of targeted molecular therapy.

Written by:
Aslam MZ, Matthews PN.   Are you the author?
Department of Urology, University Hospital of Wales, Cardiff CF14 4XW, UK.

Reference: ISRN Urol. 2014 Jan 23;2014:717295.
doi: 10.1155/2014/717295

PubMed Abstract
PMID: 24587921

UroToday.com Renal Cancer Section